ARTV Stock Analysis: Buy, Sell, or Hold?
ARTV - Artiva Biotherapeutics, Inc. Common Stock
$7.87
-0.12 (-1.50%)
▼
5d:
-19.53%
30d:
-30.35%
90d:
+63.96%
WAIT
LOW Confidence
Analysis Updated: May 22, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When ARTV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ARTV is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ARTV is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ARTV is currently trading at $7.87, which is considered oversold relative to its 30-day fair value range of $8.88 to $12.04.
Technical Outlook: Technically, ARTV is in a strong uptrend. The price is currently testing key support at $7.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.80 (+354.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARTV is in a strong uptrend. The price is currently testing key support at $7.70. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.80 (+354.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.88 -
$12.04
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 354.9% below Wall St target ($35.80)
- WARNING: Recommendation downgraded due to -19.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$8.88 -
$12.04
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.70
Resistance Level
$11.77
Current Trend
Strong Uptrend
Technical data as of
May 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.76
Wall Street Target
$35.80
(+354.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 25, 2026 12:06 PM ET
Data refreshes hourly during market hours. Next update: 1:06 PM
Data refreshes hourly during market hours. Next update: 1:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Fred Aslan
SELL
3187 shares
2025-12-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 65 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$118 | 55 HOLD |
